Stay up to date with the latest news and activities at AKESOgen.

CAP

AKESOgen Receives Accreditation from College of American Pathologists

CAP 2

Atlanta, GA – 8th February 2016 – Personalized Medicine and genomics company AKESOgen, announced today Accreditation from the College of American Pathologists (CAP).

The AKESOgen facility in Atlanta completed a comprehensive on-site inspection and analysis of its oncology testing as part of the CAP’s Accreditation Programs. The CAP Laboratory Accreditation Program involves a process of inspections of clinical lab records and quality control procedures and assessments of a lab’s staff qualifications, equipment, facilities, safety program, and overall management.

“This is an important endorsement by the College of American Pathologists for AKESOgen to provide our comprehensive cytogenomics oncology tests and services for a wide spectrum of solid and liquid tumors and will be of particular benefit to patients –as the tests are offered as a complement to NGS clinical oncology testing,” commented Gabriela M. Oprea, MD, the facility’s director.

“AKESOgen is honored to achieve accreditation from the College of American Pathologists. CAP accreditation is viewed as the ‘crème de la crème’ for laboratory testing. The whole team at AKESOgen is proud to be awarded this prestigious accreditation. This achievement strengthens our commitment to enabling Precision Medicine at the highest quality possible,” said Dr Mark Bouzyk, CSO of AKESOgen.

 About AKESOgen, Inc.

AKESOgen is an integrated genomics, genetics and bio-banking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing, and research. Based in Atlanta, GA, USA, the company’s main focus is oncology and personalized medicine. AKESOgen’s services include providing high-throughput biomarker profiling, cytogenetic arrays, sequencing, and genomics analyses utilizing different types of markers (e.g. DNA, mRNA, miRNA, and methylation). For more information, visit www.akesogen.com.

About the College of American Pathologists

As the leading organization with more than 18,000 board-certified pathologists, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. The CAP’s Laboratory Improvement Programs, initiated 65 years ago, currently have customers in more than 100 countries, accrediting 7,700 laboratories and providing proficiency testing to 20,000 laboratories worldwide. Find more information about the CAP at www.cap.org. Follow CAP on Twitter: @pathologists.

Media Contact:

Marissa Cooke, Client Relations Specialist, Scientific Affairs, AKESOgen, Inc. +1 770-542-0890 or mcooke@akesogen.com

CAP-logo-750x456

Share this facebooktwittergoogle_plusredditlinkedinmailfacebooktwittergoogle_plusredditlinkedinmail
PMWC2016

AKESOgen attend the Personalized Medicine World Conference 2016

AKESOgen scientists attend the Personalized Medicine World Conference 2016 in the Computer History Museum, Mountain View, CA, January 25 – 27, 2016.

Please email info@akesogen.com or call 770 542 0890 to discuss your genomics needs.

Share this facebooktwittergoogle_plusredditlinkedinmailfacebooktwittergoogle_plusredditlinkedinmail
Slide1

AKESOgen’s CSO wins prestigious Innovation Award at the Annual Partnership Gwinnett Summit

 

IMG_4764

IMG_4770

Atlanta, GA – 11th December 2015 – Dr. Bouzyk, a nominated finalist, was today announced as the Winner of the “Innovation” category for the Annual Partnership Gwinnett Awards.

The winners were announced at the Awards Luncheon during the Annual Partnership Gwinnett Summit at Georgia Gwinnett College. Preceding the luncheon a half-day program focused on Gwinnett’s 2015 economic successes, as well as highlighting progress in the areas of education, redevelopment, and entrepreneurship.

“ I am delighted to have received this prestigious Innovation Award on behalf of my colleagues at AKESOgen who are the real Innovators in the expanding field of genomics and Precision Medicine. We are also grateful to the Gwinnett Chamber of Economic Development for the outstanding infrastructure and support they provide to enable life science companies such as AKESOgen to flourish.” commented Dr. Bouzyk.

 About AKESOgen, Inc.

AKESOgen is an integrated genomics, genetics and bio-banking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing, and research. Based in Atlanta USA, the company’s main focus is oncology and personalized medicine. AKESOgen’s services include providing high-throughput, biomarker profiling, cytogenetic arrays, sequencing, and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, and methylation) to CLIA/GLP standards. For more information, visit www.akesogen.com

Media Contact:

Crystal Yang, Client Relations Specialist, Scientific Affairs, AKESOgen, Inc. +1 770-542-0890 ext 101 (office), or cyang@akesogen.com

Share this facebooktwittergoogle_plusredditlinkedinmailfacebooktwittergoogle_plusredditlinkedinmail
inc500-logo

AKESOgen makes Annual List of America’s Fastest-Growing Private Companies—the Inc.500

HighResLog-old

AKESOgen makes Annual List of America’s Fastest-Growing Private Companies—the Inc.500

AKESOgen Ranks as the No. 44 Healthcare Company and 363rd Overall on the 2015 Inc.500 with Three-Year Sales Growth of 1,300%

NEW YORK and ATLANTA, August 12, 2015Inc. magazine today ranked the genomics services provider, AKESOgen, 44th as a Healthcare company and 363rd overall on its 34th annual Inc.500|5000, an exclusive ranking of the nation’s fastest-growing private companies. The list represents the most comprehensive look at the most important segment of the economy—America’s independent entrepreneurs. Companies such as Intuit, Zappos, Under Armour, Microsoft, GoPro, Timberland, Clif Bar, Patagonia, Oracle, and many other well-known names gained early exposure as members of the Inc.500|5000.

“We are delighted to be recognized as an Inc.500 honoree with such well known organizations in 2015 as Fitbit, Smashburger, Bowlmor AMF, Planet Fitness, Giftcards.com, Radio Flyer, Box, and Mindbody.” commented AKESOgen CEO Robert Boisjoli.

“Genetics and Precision Medicine are becoming more and more pervasive in our society. As a result, there is an unprecedented need for genomics capabilities in clinical trials and diagnostics, in addition to research. AKESOgen is at the forefront of providing these molecular technologies for 21st century personalized medicine.” says Mark Bouzyk, AKESOgen’s CSO.

This year’s crop of Inc.500 companies is the most competitive in the list’s history. “For 34 years, Inc. has welcomed the fastest-growing companies in America into a very exclusive club. To make it among the top 500 companies on the list, honorees had to have grown at least tenfold over the past three years. That’s a result most businesses could only dream of…” says Inc. President and Editor-In-Chief Eric Schurenberg.

Complete results of the Inc.500|5000, including company profiles and an interactive database that can be sorted by industry, region, and other criteria, can be found at www.inc.com/inc500.

About Inc. Magazine

Founded in 1979 and acquired in 2005 by Mansueto VenturesInc. Magazine is the only major brand dedicated exclusively to owners and managers of growing private companies.  Total monthly audience reach for the brand has reached over 6,000,000 in 2015.  For more information, visit www.inc.com

About AKESOgen, Inc.

AKESOgen is an integrated genomics, genetics and bio-banking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing, and research. Based in Atlanta USA, the company’s main focus is oncology and personalized medicine. AKESOgen’s services include providing high-throughput, biomarker profiling, cytogenetic arrays, sequencing, and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, and methylation) to CLIA/GLP standards. For more information, visit www.akesogen.com

Media Contact:

Crystal Yang, Client Relations Specialist, Scientific Affairs, AKESOgen, Inc. +1 770-542-0890 ext 101 (office), or cyang@akesogen.com

Share this facebooktwittergoogle_plusredditlinkedinmailfacebooktwittergoogle_plusredditlinkedinmail
ICB-mark presenting

AKESOgen’s CSO delivers plenary lecture at the third annual International Conference on Biomarkers Discovery and Clinical Application, Shanghai, China

 

Shanghai, China– 17th-18th October, 2015- Personalized medicine and genomics company, AKESOgen, attended and spoke at the third annual International Conference on Biomarkers Discovery and Clinical Application (ICB) in Shanghai, China  as an industry expert on genomic profiling in multiple cancers.  The ICB brought together international pharmaceutical, biotech and diagnostics companies, leading universities and institutions, healthcare, government, and national labs, CROs and tool providers.  The third annual ICB focussed on the following:

  • Trends in Biomarker Research
  • Biomarkers and translational medicine
  • Biomarkers in drug development
  • Innovation in biomarker discovery

“International conferences such as the ICB marks the impact that genomic information, shared internationally, can provide to improving precision medicine” said Mark Bouzyk, CSO of AKESOgen.

ICB logo-Shanghai           AKESOgen-Logo333

About AKESOgen, Inc.
AKESOgen is an integrated genomics, genetics and biobanking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing and research. Based in Atlanta USA, the company’s main focus is oncology and personalized medicine. AKESOgen’s services include providing high-throughput, biomarker profiling, cytogenetic arrays and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, and methylation) to CLIA/GLP standards. For more information, visit www.akesogen.com.

Media Contacts:

Mark Bouzyk, PhD, Chief Scientific Officer. AKESOgen, Inc. +1 770-542-0890 ext 101 (office), or mbouzyk@akesogen.com

Share this facebooktwittergoogle_plusredditlinkedinmailfacebooktwittergoogle_plusredditlinkedinmail
ASHG Logo-2015

AKESOgen at ASHG

AKESOgen scientists attended ASHG in Baltimore, MD, October 7-
9, 2015. Please email info@akesogen.com or call 770 542 0890 to discuss your genomics needs.

HighResLog-oldMark_at_ASHG15ASHG Logo-2015

Share this facebooktwittergoogle_plusredditlinkedinmailfacebooktwittergoogle_plusredditlinkedinmail
Unknown

NSH Molecular Course Outline October 26-28 2015

 

AKESOgen-Logo333targos logo

AKESOgen, a leader in personalized medicine and genomics, has partnered with Targos and the National Society of Histotechnology to create and assemble an inaugural course on In-situ Hybridization, Microarray & Next-Generation Sequencing in Clinical Diagnostics.  The course will be held at the Emory conference center on Oct 26th-28th, 2015.  Please click the link below to view the agenda.  Additionally, the course will provide CEU credits.

NSH Molecular Course Outline October 26-28 2015

 

Emory Conference Center Hotel

Please click the link below to register for the course.

Registration of NSH Molecular Course Outline October 26-28 2015

About AKESOgen, Inc. 

AKESOgen is an integrated genomics and pharmacogenetics company providing biorepository services and high-throughput, biomarker profiling and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, methylation) for the clinical and R&D market to CLIA standards. A private company based in Atlanta, GA, AKESOgen is a genomics contract research organization that services the academic, pharmaceutical, biotechnology, clinical testing and government sectors. AKESOgen provides expertise in biobanking, assay development and all ancillary services in a purpose-built facility. For more information, visit www.akesogen.com.

About the National Society of Histotechnologists

NSH is the premier source of learning, knowledge and future-oriented research for histology professionals. Attendance provides resources, education, ideas and advocacy to enhance the performance in the laboratory and ultimately the best patient care.

http://www.histoconvention.org/

Share this facebooktwittergoogle_plusredditlinkedinmailfacebooktwittergoogle_plusredditlinkedinmail
bio1

AKESOgen to host and sponsor Industry tour on behalf of Georgia Bio

Please join Georgia Bio’s Emerging Leaders Network on their Industry Tour for an inside look of AKESOgen, a premier provider of genetic analysis.

This industry tour will provide participants an inside look of AKESOgen, a leader in personalized medicine and genomics.  Equipped with industry experts, AKESOgen provides high quality genomic analysis services, performing over 21,000 whole genome genotyping monthly. It is the only facility in the United States that has developed and performs clinical commercial copy number alteration (CNA) microarray analysis for formalin-fixed, paraffin-embedded (FFPE) tissue samples on Illumina platforms. AKESOgen provides contract research, clinical diagnostic and clinical trial services to pharmaceutical, biotech, academic, and government research institutions.  The company supported over 100 academic investigators in 2014.

All participants should be dressed smart casual with closed toe shoes.

To register for this event and further details please go to: http://www.gabio.org/events/event_details.asp?id=600212

When:
Wednesday, September 09, 2015
10:30 am – 12:30 pm

Share this facebooktwittergoogle_plusredditlinkedinmailfacebooktwittergoogle_plusredditlinkedinmail

CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1–98 trial

CYP19A1 polymorphisms and clinical outcomes
in postmenopausal women with hormone receptor-positive
breast cancer in the BIG 1–98 trial

Leyland-Jones B, Gray KP, Abramovitz M, Bouzyk M, Young B, Long B, Kammler R, Dell’Orto P, Biasi MO, Thürlimann B, Lyng MB, Ditzel HJ, Harvey VJ,Neven P, Treilleux I, Rasmussen BB, Maibach R, Price KN, Coates AS, Goldhirsch A, Pagani O, Viale G, Rae JM, Regan MM.

Breast Cancer Res Treat. 2015 Jun;151(2):373-84. doi: 10.1007/s10549-015-3378-3. Epub 2015 May 3.

PMID:24814193

Share this facebooktwittergoogle_plusredditlinkedinmailfacebooktwittergoogle_plusredditlinkedinmail